Axel Grothey, MD, provides an overview of the KEYNOTE-177 trial in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.
Axel Grothey, MD, medical oncologist and director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, provides an overview of the KEYNOTE-177 trial in patients with microsatellite instability–high (MSI-H) and mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
The KEYNOTE-177 trial was a randomized study examining the use of first-line pembrolizumab (Keytruda) versus chemotherapy—specifically investigator's choice of doublet chemotherapy with or without a biologic agent—in patients with MSI-H/dMMR mCRC, Grothey explains. This patient subgroup is rare, comprising only about 4%to5% of allCRCs, according to Grothey. However, once identified, this patient population haseffective treatment options through the addition of immunotherapy.
In the trial, which comprised 307 patients, data showed thatpembrolizumabled tomarked improvementsin progression-free survivalover chemotherapy, Grothey concluded.